Mumbai, March 10 -- As on 31st December 2025, the company's promoter shareholding stood at 67.39%.

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.

The company's standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.

Published by HT Digital Content Services with permission from Capital Market....